Neuroblastoma | CHOP Research Institute
 

Neuroblastoma

This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory).
Published on
Mar 25, 2024
Rochelle Bagatell, MD, chaired the multidisciplinary panel that developed the NCCN guidelines, which will help to direct treatment of a highly heterogeneous disease.
Published on
Mar 5, 2024
Two global teams are developing solid cancer drugs and understanding T-cell receptors.
Published on
Jan 30, 2024
Dr. Maris is co-leading a study that aims to develop patient-specific cancer vaccines that could be applied to patients in remission to prevent relapse.
Published on
Nov 10, 2023
This week’s research news features awards for furthering patient-centered outcomes research careers and for recognizing the importance of mentorship.
Published on
Apr 14, 2023
Learn about a technique to analyze large datasets, preclinical results that show safety and efficacy of a drug that could help children with high-risk neuroblastoma, and a milestone in the CORSICA project that seeks to cure rare sinonasal cancers.

Dr. Wolpaw’s laboratory seeks to develop an understanding of how tumor heterogeneity and epigenetics impact inflammatory signaling and immunotherapy responses in pediatric solid tumors with a goal of developing more efficacious, less toxic therapies to treat these devastating diseases.

Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Dr. Evageliou is an attending physician in the Division of Oncology. His research interest is in renal tumors, neuroblastoma, and solid tumors. He is a member of the Renal Tumors Committee of the Children's Oncology Group, where he helps create clinical trials for Wilms tumors.

E-mail:
evageliou [at] chop.edu
Published on
Jun 29, 2022
CHOP scientists are part of a Cancer Grand Challenges team receiving $25 million to tackle solid tumors.